Key result
This review summarizes important randomized controlled trials and guidelines for using SGLT-2 inhibitors in patients with heart failure and chronic kidney disease.
Why the study?
Heart failure and chronic kidney disease remain major causes of morbidity and mortality despite current therapies, necessitating updated guidance on SGLT-2 inhibitors.
Do SGLT-2 inhibitors improve outcomes in patients with heart failure and chronic kidney disease?
Do SGLT-2 inhibitors improve outcomes in patients with heart failure and chronic kidney disease?
This review summarizes the evidence and guidelines supporting the use of SGLT-2 inhibitors as standard-of-care therapy for heart failure and chronic kidney disease.
SGLT2 inhibitors remain standard for HF and CKD; reinforces RCT evidence for clinic and hospital use.
Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.
No takes yet. Share an insight, caveat, or question.
Jaswaney et al. (2024) conducted a review in Heart failure and chronic kidney disease. SGLT-2 inhibitors was evaluated. This review summarizes important randomized controlled trials and guidelines for using SGLT-2 inhibitors in patients with heart failure and chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: